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Abstract
RhoA is a member of the Rho family small GTPases that are implicated in various cell functions including proliferation and
survival. However, the physiological role of RhoA in vivo remains largely unknown. Here, we deleted RhoA in the B cell and
hematopoietic stem cell (HSC) populations in RhoA
flox/flox mice with CD19 and Mx promoter-driven Cre expression,
respectively. Deletion of RhoA by CD19
Cre/+ significantly blocked B cell development in spleen, leading to a marked
reduction in the number of transitional, marginal zone, and follicular B cells. Surprisingly, neither B cell proliferation in
response to either LPS or B cell receptor (BCR) engagement nor B cell survival rate in vivo was affected by RhoA deletion.
Furthermore, RhoA
2/2 B cells, like control cells, were rescued from apoptosis by BCR crosslinking in vitro. In contrast, RhoA
deficiency led to a defect in B cell activating factor (BAFF)-mediated B cell survival that was associated with a dampened
expression of BAFF receptor and a loss of BAFF-mediated Akt activation. Finally, HSC deletion of RhoA by Mx-Cre severely
reduced proB/preB and immature B cell populations in bone marrow while common lymphoid progenitors were increased,
indicating that RhoA is also required for B cell progenitor/precursor differentiation. Taken together, our results uncover an
important role for RhoA at multiple stages of B cell development.
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Introduction
B lymphocytes differentiate from bone marrow hematopoietic
stem cells (HSCs) through a series of developmental stages [1–4].
In the first stage, B cell progenitors, or proB cells, undergo
immunoglobulin heavy chain gene rearrangement to differentiate
into preB cells. PreB cells then undergo immunoglobulin light
chain gene rearrangement to further develop into immature B
cells. Immature B cells emigrate from the bone marrow to the
spleen, where they become transitional (T) B cells. Although a
small proportion of T B cells mature into non- circulating
marginal zone (MZ) B cells, most differentiate into follicular (FO)
B cells that circulate to spleen follicles, lymph nodes, and bone
marrow.
RhoA is an intracellular signal transducer of the Rho family
small GTPases that cycles between an inactive GDP-bound form
and an active GTP-bound form under tight regulation [5,6].
Activated RhoA binds to a variety of effector molecules (e.g.
ROCK and mDia) to modulate actin cytoskeleton organization,
adhesion, migration, proliferation, and survival in mammalian
cells [7–11]. In B cells, RhoA transduces signals from the B cell
receptor (BCR) to regulate phosphatidylinositol-4, 5-bisphosphate
synthesis, PLCc2 activation, calcium influx, protein kinase D
activation, and B cell proliferation [12,13]. RhoA also plays a role
in CCL19- and CCL21-induced migration of B-chronic lympho-
cytic leukemia cells [14]. However, the role of RhoA in B cell
development remains unknown, although three closely related
members of Rho GTPases, Rac1, Rac2, and Cdc42 are all
required for B cell differentiation [15,16]. The majority of
published literatures for RhoA have employed overexpression of
constitutively active or dominant negative RhoA mutants. While
this strategy has resulted in a number of key discoveries, including
the critical role of RhoA in actin stress fiber formation and cell
adhesion [7], it is compromised by the promiscuous nature of these
RhoA mutants [17–20]. For instance, RhoA dominant negative
mutants sequester upstream guanine nucleotide exchange factors
(GEFs) that are capable of activating additional Rho GTPases,
potentially leading to non-specific phenotypes. In addition,
overexpression of constitutively active GTP-bound RhoA mutants
might activate a number of effectors (e.g., ROCK) shared between
RhoA and other Rho GTPases, potentially causing off-target
effects. Finally, a strictly balanced RhoA GTP-binding/GTP-
hydrolysis cycle is required for proper signaling. As such, the
overexpression of these mutants might introduce artifacts by
locking RhoA into a single conformation at a fixed intracellular
location. It is therefore highly desirable to use a gene targeting
strategy to assess the physiological functions of RhoA.
Several studies have reported the use of RhoA conditional gene
targeting to define RhoA functions in mice [21–23]. Deletion of
RhoA in skin cells revealed that, while RhoA is not required for
skin development, it is indispensible for the contraction and
directed migration of primary keratinocytes. In the nervous
system, RhoA maintains adherens junctions and modulates
neuronal cell proliferation. Furthermore, contrary to the conven-
tional view that RhoA is essential for actin cytoskeleton
rearrangement and cell adhesion, RhoA-deficient primary mouse
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focal adhesion complex formation. Nonetheless, RhoA is critical
for MEF cell proliferation.
To assess the physiological role of RhoA in B cell development,
we generated mouse strains deficient for RhoA expression in either
B cells or HSCs by crossing RhoA
flox/flox mice with CD19
Cre/+ or
Mx-Cre transgenic mice. Using these targeted deletion models, we
demonstrate that RhoA is crucial for B cell development and for B
cell activating factor (BAFF)-mediated B cell survival, but not for
BCR-mediated proliferation and survival.
Results
Generation of RhoA-deficient B cells by CD19
Cre/+
To study the role of RhoA in B cell development, RhoA
flox/flox
mice [22,23] were crossbred with CD19
Cre/+ transgenic mice to
generate CD19
Cre/+; RhoA
flox/flox (RhoA
2/2) mice (Fig. 1A). Because
CD19
Cre/+ transgenic mice are generated by inserting the Cre gene
into the CD19 locus, the transgenic mice are depleted of one copy
of the CD19 gene, which may affect B cell development [24]. We
thus used CD19
Cre/+; RhoA
+/+ mice, but not RhoA
flox/flox mice, as
control for RhoA
2/2 mice. B220
+ B cells were purified from the
bone marrow and spleen of RhoA
2/2 and control mice. Western
blot analysis indicated that RhoA expression was dramatically
reduced in splenic B cells, but less so in bone marrow B cells in the
mutant mice (Fig. 1A).
Effects of RhoA deletion on B cell development
To determine if RhoA deficiency affects B cell development, we
performed FACS analysis of B cells at various stages of
differentiation. We did not detect significant changes in either the
percentage or number of ProB/PreB cells (B220
loIgM
2)o r
immature B cells (B220
loIgM
+)i nRhoA
2/2 mice (Fig. 1B), likely
due to the demonstrated inefficient RhoA deletion in bone marrow
B cells (Fig. 1A). In contrast, RhoA
2/2 mice displayed a reduction in
recirculating B cells (B220
hiIgM
+) in bone marrow (Fig. 1B),
suggesting that late splenic B cell development is altered by the
disruption of RhoA expression. Indeed, the number of all splenic B
subsets, including T (B220
+CD21
2CD23
2), MZ (B220
+CD21
+
CD23
2) and FO (B220
+CD21
+/2CD23
+) B cells, was drastically
decreased in RhoA
2/2 mice, although the frequency of T and FO B
cells was only marginally affected (Fig. 1C). In agreement,
hematoxylin and eosin staining of RhoA
2/2 spleen sections revealed
lymphoid hypoplasia and loss of follicular architecture (Fig. 1D).
Moreover, B cells were decreased in the lymph nodes and blood in
the absence of RhoA (data not shown). Taken together, these results
suggest that RhoA is critical for the late B cell development.
Effects of RhoA deletion on B cell proliferation and
survival
Cell proliferation is crucial for B cell development [4]. To
explore the mechanisms underlying impaired splenic B cell
development in RhoA-deficient mice, we determined the prolif-
erative capacity of RhoA
2/2 splenic B cells upon in vitro culture
with either LPS or anti-IgM F(ab’)2 antibody to crosslink BCR.
Surprisingly, we found that under either condition the RhoA
2/2 B
cell proliferation profile did not statistically differ from control cells
(Fig. 2A). These results suggest that RhoA is dispensable for Toll-
like receptor- or BCR-mediated B cell proliferation. Along with
recent studies showing that RhoA-deficient neural progenitor cells
are hyperproliferative while RhoA-deficient MEFs have impaired
proliferation [22,23], it appears that RhoA plays cell type-specific
roles in the regulation of cell proliferation.
B cell survival constitutes another important requirement for B
cell development [2]. Since RhoA reportedly regulates cell survival
[6], we examined the survival index of RhoA-deficient B cells by
Annexin V staining and found that Ex vivo splenic B cells from
RhoA
2/2 mice had no detectable survival defect (Fig. 2B).
Moreover, control and RhoA2/2 B cells cultured in vitro with
anti-IgM F(ab’)2 antibody exhibited a similar increase in survival
induced by BCR ligation (Fig. 2C). However, RhoA
2/2 B cells
were resistant to B cell survival factor BAFF-mediated apoptosis
inhibition while control B cells were rescued from apoptosis by
BAFF in a dose-dependent manner (Fig. 2C). Interestingly,
treatment with Y27632, a chemical inhibitor of the RhoA
downstream effector ROCK, partially blunted the survival
response of control B cells to BAFF (Fig. 2C), suggesting that
RhoA modulates BAFF-mediated B cell survival, at least in part,
through activation of ROCK. The lack of a survival response of
RhoA
2/2 B cells to BAFF correlates with a reduction of BAFF
receptor (BAFFR) on T, FO, and MZ B cells, as demonstrated by
a reduction of BAFFR
+ cells and the mean fluorescence intensity
per cell (Fig. 2D). The reduction of cell surface BAFFR is not likely
due to a trafficking defect since Western blot revealed that
RhoA
2/2 B cells had a 50% reduction in BAFFR protein
expression compared to control B cells (Fig. 2E). Quantitative
real-time PCR analysis demonstrated a reduction of BAFFR
mRNA in RhoA
2/2 B cells, suggesting that the reduction in
BAFFR protein is due to reduced transcription and not a
reduction in protein stability (Fig. 2F). Indeed, RhoA deficiency
completely abolished BAFF-mediated Akt activation, likely due to
decreased BAFFR expression (Fig. 2G). In contrast to BAFFR,
RhoA deficiency had no effect on BCR expression as revealed by
comparable levels of IgM in control and RhoA
2/2 B cells (Fig. 2E),
in agreement with the normal proliferative or survival response of
RhoA
2/2 B cells to BCR ligation. Collectively, these results suggest
that RhoA selectively regulates BAFF-mediated B cell survival by
controlling BAFFR expression.
Effects of HSC deletion of RhoA on B cell precursor
development in bone marrow
As previously demonstrated, CD19
Cre/+-mediated RhoA deletion
in bone marrow B cells is inefficient (Fig. 1A), precluding further
examination of the role of RhoA in their development. Instead, we
employed an alternatively method to generate RhoA
2/2 HSCs by
crossing RhoA
flox/flox with Mx-Cre transgenic mice and inducing Cre
expression in Mx-Cre; RhoA
flox/flox mice with polyI:C (Fig. 3A).
RhoA
flox/flox littermates were used as control and also treated with
polyI:C. Since Mx-Cre; RhoA
flox/flox mice die within eight days after
polyI:C induction, we analyzed the mice at day six and found that
RhoA was almost completely absent from the bone marrow
(Fig. 3A). FACS analysis indicated that both the percentage and
number of common lymphoid progenitors (CLP) were elevated in
Mx-Cre; RhoA
flox/flox mice(Fig.3B),buttheproB/preB and immature
B cell subsets were markedly decreased (Fig. 3C). The percentage,
but not number, of recirculating mature B cells in bone marrow was
increased in Mx-Cre; RhoA
flox/flox mice (Fig. 3C and data not shown),
likely due to a compensatory effect of the decreased proB/preB and
immature B cells. These results suggest that RhoA deficiency
inhibits bone marrow B cell development at the CLP differentiation
stage. Thus, RhoA also plays a critical role in early B cell
development.
Discussion
In this study, we have shown that RhoA deletion in B cells by
CD19
Cre/+ causes a defect in splenic B cell development that is
RhoA in B Cell Development
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33773associated with an impaired BAFF-mediated survival response.
Accordingly, BAFFR expression and BAFFR-mediated Akt
activation are dampened in RhoA-deficient B cells. We have also
demonstrated that depletion of RhoA from HSCs by Mx-Cre
results in an earlier developmental defect at the transition of CLP
to proB/preB cells. These data suggest that RhoA plays critical
roles in both early and late stages of B-cell development.
The B cell developmental phenotypes in RhoA
2/2 mice show
some similarities as well as differences from mice deficient for the
other Rho family GTPases, Cdc42, Rac1 and/or Rac2 [15,16,25].
For instance, RhoA
2/2, Cdc42
2/2 and Rac1
2/2Rac2
2/2 mice all
have decreased numbers of T, FO and MZ B cells while Rac2
2/2
mice show a reduction only in MZ B cells [15,16,25]. Additionally,
defective BAFF-mediated B cell survival signaling is observed in all
RhoA
2/2, Cdc42
2/2 and Rac1
2/2Rac2
2/2 mice [15,16]. In
contrast, RhoA deficiency has no effect on BCR-mediated cell
proliferation, whereas ablation of either Cdc42, Rac2 or both
Rac1 and Rac2 dampens BCR signaling and cell proliferation
[15,16,25]. Moreover, deletion of Rac2 or both Rac1 and Rac2,
but not Cdc42, compromises B cell migration [16,25,26], which is
thought to play a role in B cell development [27]. It remains to be
determined whether depletion of RhoA affects B cell migration.
These data combined with our findings suggest that different
aspects of B cell development may require distinct Rho GTPases.
The lack of response of RhoA
2/2 B cells to BCR-mediated cell
proliferation might be due to functional redundancy of other Rho
GTPase family members, including Cdc42, Rac1, and Rac2, or
compensatory activation of RhoB and/or RhoC [15,16,25]. We
could not detect an effect of RhoA deficiency on bone marrow B
cell development, potentially due to the poor deletion efficiency of
CD19
Cre/+ in these cells. Indeed, CD19
Cre/+ is reportedly less
efficient in deleting polb in preB cells than in splenic B cells [28].
Furthermore, we have observed that CD19
Cre/+ only partially
deletes Cdc42 in proB/preB cells [16]. As such we speculate that
the residual RhoA expression in RhoA
2/2 bone marrow B cells is
attributable to the incomplete deletion of RhoA in proB/preB
cells. So to study the role of RhoA in bone marrow B cell
development, we instead used Mx-Cre to remove RhoA from
HSCs. Noting that Mx-Cre; RhoA
flox/flox mice die within eight days
after polyI:C injection, likely due to severe anemia, we analyzed
Figure 1. B cell-specific deletion of RhoA impairs splenic B cell development. (A) Generation of RhoA
2/2 B cells. Left, the loxP/Cre-mediated
gene targeting strategy to generate the RhoA knockout allele (RhoA
2) in B cells. Right, Western blot showing RhoA expression in B220
+ B cells
purified from bone marrow and spleen of CD19
Cre/+; RhoA
+/+ (control) and CD19
Cre/+; RhoA
flox/flox (RhoA
2/2) mice. (B) Bone marrow cells from control
and RhoA
2/2 mice were stained with antibodies against B220 and IgM and analyzed by flow cytometry (left). The number of B cell subsets was
calculated by multiplying the total number of bone marrow cells by the percentage of each subset of cells (right). n=5. (C) Splenocytes from control
and RhoA
2/2 mice were stained with antibodies against B220, CD21 and CD23 and analyzed by flow cytometry (left). The number of B cell subsets
was calculated by multiplying the total number of splenocytes by the percentage of each subset of cells (right). T: transitional B cells, FO B: follicular B
cells, and MZ B: marginal zone B cells. n=5. (D) Spleen sections from control and RhoA
2/2 mice, stained with hematoxylin and eosin. Data are
representative of 3 mice. Error bars represent mean 6 SD. **p,0.01. Statistical analysis was performed using a Student’s unpaired t-test with a two-
tailed distribution.
doi:10.1371/journal.pone.0033773.g001
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+ B cells from CD19
Cre/+; RhoA
+/+
(control) and CD19
Cre/+; RhoA
flox/flox (RhoA
2/2) mice were cultured for 48 hours on 96-well plates (4610
5 cells/well) with or without (2)2mg/mL anti-
IgM F(ab’)2 antibody or LPS. Cell growth rate was analyzed using the CellTiter 96H AQueous Non-Radioactive Cell Proliferation Assay (MTS) kit. Data are
expressed as absorbance OD490. n=5. (B) Splenocytes from control and RhoA
2/2 mice were stained with anti-B220, -CD21, and -CD23 antibodies
followed by Annexin V staining. The cells were then analyzed by flow cytometry. T: transitional B cells, FO B: follicular B cells, and MZ B: marginal zone
B cells. n=5. (C) Splenic B220
+ B cells from control and RhoA
2/2 mice were cultured for 72 hours on 96-well plates (2610
5 cells/well) with or without
(2)2mg/mL anti-IgM F(ab’)2 antibody or indicated concentrations of BAFF (left). Alternatively, control B cells were incubated with or without (2)
BAFF and/or Y27632 (10 mM) (right). The cells were then stained with Annexin V and analyzed by flow cytometry. n=5. (D) Splenocytes from control
and RhoA
2/2 mice were stained with antibodies against B220, CD21, CD23 and BAFFR, and then analyzed by flow cytometry. The numbers above
bracketed lines indicate the percentage of BAFFR
+ cells in each B cell subset and the numbers below the bracketed lines indicate mean fluorescence
intensity (MFI) of BAFFR in each B cell subset (left). The percentage of BAFFR
+ cells and MFI of BAFFR were averaged from 5 mice for each genotype
(right). (E) Splenic B220
+ B cells from control and RhoA
2/2 mice were subjected to Western blot for BAFFR and IgM (left). b-actin serves as loading
control (left). The protein expression was quantified and normalized to b-actin and the data are expressed as fold of expression (right). n=3. (F)
Splenic B220
+ B cells from control and RhoA
2/2 mice were analyzed for BAFFR mRNA levels by quantitative RT-PCR. The expression of GAPDH was
used to normalize samples and the relative fold of expression is shown. n=4. (G) Splenic B220
+ B cells from control and RhoA
2/2 mice were
stimulated with or without BAFF(100 ng/mL) for 30 min and then subjected to Western blot (left). Phospho (p)-Akt (S473) is quantified and
normalized to total Akt and the data are expressed as relative fold of p-Akt (right). n=3. Error bars represent mean 6 SD. **p,0.01. *p,0.05.
Statistical analysis was performed using a Student’s unpaired t-test with a two-tailed distribution.
doi:10.1371/journal.pone.0033773.g002
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deficiency blocked CLP differentiation to proB/preB and
subsequent immature B cells. We also examined B cell maturation
in the spleen of Mx-Cre; RhoA
flox/flox mice, but no abnormalities
were observed in the numbers of T, FO and MZ B cells (data not
shown). We postulate that the intact splenic B cell differentiation in
Mx-Cre; RhoA
flox/flox mice may be due to a perturbation of
preexisting splenic B cells that can live relatively longer than bone
marrow B cells and therefore may not be lost by six days post
polyI:C induction. Thus, the combined use of Mx-Cre; RhoA
flox/flox
and CD19
Cre/+; RhoA
f lox/f lox mouse models has allowed us to
investigate specific roles for RhoA in both early bone marrow and
late splenic B cell development.
The survival of peripheral B cells is regulated by BCR and
BAFFR [29]. Interestingly, we find that RhoA selectively regulates
BAFF/BAFFR- but not BCR-mediated survival. Hence, RhoA
appears to play a stimulus-specific role in B cell survival. This
concept is supported by a number of observations in other cell
types. For instance, RhoA is important for thrombin-induced
ICAM-1 expression, but not for the induction of ICAM-1
expression by TNFa, in endothelial cells [30]. In chondrocytes,
RhoA regulates TGF-b- but not IL-1-induced actin cytoskeleton
reorganization [31]. Furthermore, RhoA mediates TNFa- but not
UV-induced NF-kB activation in COS-7 cells [32].
Since BAFFR expression is reduced in RhoA
2/2 splenic B cells,
RhoA may regulate BAFF/BAFFR-mediated B cell survival by
modulating BAFFR expression. In addition to its primary
functions in regulating BAFF-induced B cell survival, homeostasis
and differentiation [29,33–36], BAFFR has also been shown to
regulate the production of naturally occurring IgM, IgG1 and T
cell-dependent IgG and to be involved in T-cell independent class
switch to IgG and IgE [35,36]. It is therefore plausible that RhoA
might play a role in antibody formation. BAFFR has recently been
shown to regulate B cell chemotaxis [37]. It is conceivable then
that RhoA contributes to B cell chemotaxis via regulation of
BAFFR expression. Finally, literature indicates that BAFFR is
required for CD21 and CD23 expression [36], so RhoA could
regulate the differentiation of FO and MZ B cells by affecting
BAFFR-mediated expression of FO and MZ B cell surface
markers.
Materials and Methods
Ethics statement
This study involved the use of mice and was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the Cincinnati Children’s
Hospital Research Foundation. The protocol was approved by the
Figure 3. RhoA is required for bone marrow B cell development. (A) Mx-Cre; RhoA
flox/flox(RhoA
2/2) mice were injected with polyI:C to delete
RhoA in HSCs (left). RhoA
flox/flox mice were used as control and also subjected to polyI:C injection. Whole bone marrow was isolated from RhoA
2/2 and
control mice and analyzed for RhoA expression by Western blot (right). (B) Bone marrow cells from RhoA
2/2 and control mice were stained for IL-7R,
lineage (Lin) markers (B220, CD3, CD4, CD8, Gr1, CD11b and TER119), Sca-1, and c-Kit followed by flow cytometry analysis. Common lymphoid
progenitor (CLP) cells (Sca1
+c-kit
+) were gated from a Lin
2IL-7R
+ cell population (left). The number of CLPs was calculated by multiplying the total
number of bone marrow cells by the percentage of CLP cells (right). n=4. (C) Bone marrow cells from RhoA
2/2 and control mice were stained with
antibodies against B220 and IgM and analyzed by flow cytometry (left). The number of B cell subsets was calculated by multiplying the total number
of bone marrow cells by the percentage of each subset of cells (right). n=4. Error bars represent mean 6 SD. **p,0.01. *p,0.05. Statistical analysis
was performed using a Student’s unpaired t-test with a two-tailed distribution.
doi:10.1371/journal.pone.0033773.g003
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Children’s Hospital Research Foundation (permit Number:
8D06052). Mice were anesthetized using ketamine (80–100 mg/
kg IM), aceptromazine (4–6 mg/kg IM) and atropine (0.1 mg/kg
IM) and anesthesia was maintained using ketamine (30 mg/kg IM)
as needed. During the course of experiments, mice were isolated in
microisolator cages and cared for by trained technician and
veterinarians of the Laboratory Animal Resource Center. Animals
were checked daily by qualified laboratory personnel. Euthanasia
was performed by CO2. This method was approved by the Animal
Care and Use Committee of the Cincinnati Children’s Hospital
Research Foundation and consistent with the recommendations of
the Panel on Euthanasia of the American Veterinary medical
Association.
Mouse gene targeting
Conditionally targeted RhoA
flox/flox mice were generated as
previously described [22,23]. The floxed allele contains loxP sites
flanking exon 3 of the RhoA allele (allele symbol: Rhoa
tm1Yuyo [22]).
To delete RhoA in vivo in the B cell lineage, RhoA
flox/flox mice were
mated with mice expressing Cre recombinase under the control of a
CD19 proximal promoter (allele symbol: CD19
tm1(cre)Cgn [24])
(Jackson Laboratory). Mice used for experiments ranged in age from
six to twelve weeks. To delete RhoA in vivo in HSCs, Mx-Cre;
RhoA
flox/flox mice were generated by breeding RhoA
flox/flox mice to Mx-
Cre transgenic mice carrying a bacteriophage Cre recombinasedriven
by an interferon-a-inducible Mx promoter (allele symbol: Tg(Mx1-
cre)29-4Her [38]) (gift of Dr. Stuart H. Orkin, Dana-Farber Cancer
institute, Boston). The expression of Mx-Cre was induced by two
intraperitoneal (IP) injections of 300 mg of polyI:C (Amersham
Pharmacia Biotech Inc) into six to twelve week old mice. Bone
marrow cells were analyzed six days post polyI:C injection. Animals
were housed under specific pathogen-free conditions in the animal
facility at Cincinnati Children’s Hospital Research Foundation.
Immunoblotting
B cells were purified from bone marrow and spleen using B220
Microbeads (Miltenyi Biotec). Total bone marrow cells and
purified B cells were lysed and protein content was normalized
by Bradford assay. Lysates were separated by 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis. Western blot was
performed using the following antibodies: RhoA (67B9), phos-
pho-Akt (D9E), and Akt (C67E7) (Cell Signaling Technology),
IgM (m chain specific) (Jackson ImmunoResearch Laboratories),
and BAFFR (G-20) (Santa Cruz).
Characterization of B cell development by cell surface
staining
Single cell suspensions were prepared from bone marrow and
spleen. Cells were incubated with various combinations of the
following antibodies at room temperature for 20 minutes: B220
(RA3-6B2), CD21 (7G6), CD23 (B3B4), CD3 (145-2C11), CD4
(RM4-5), CD8 (53-6.7), Gr1 (RB6-8C5), CD11b (M1/70),
TER119 (TER-119), c-kit (2B8), and Sca1 (D7) (BD Biosciences)
and IL7Ra (A7R34) and BAFFR (eBio7H22-E16) (eBioscience).
Flow cytometry analysis was performed on a FACSCanto system
using FACSDiVa software (BD Biosciences).
Cell apoptosis analysis
B cells were purified from spleen using B220 microbeads. The
cells were cultured for 72 hours on 96-well plates at a density of
10
6 cells/mL in 200 mL of B cell culture medium (10% fetal calf
serum; 10 mM Hepes pH 7.3; L-glutamine; Penicillin/Strepto-
mycin; non-essential amino acids; sodium pyruvate; and 5610
25
M 2-mercaptoethanol, in RPMI-1640) in the presence or absence
of 2 mg/mL of anti-IgM F(ab’)2 antibody (Jackson Immunore-
search Laboratories), or various concentrations of recombinant
human BAFF (PeproTech). The cultured B cells and ex vivo B cells
were then stained with Annexin V (BD Biosciences) followed by
flow cytometry analysis.
Cell proliferation assay
Purified splenic B cells were cultured for 48 hours on 96-well
plates at 2610
6 cells/mL in 200 mL of B cell culture medium in
the presence or absence of 2 mg/mL of either anti-IgM F(ab’)2
antibody or LPS. Cell growth rate was analyzed by using the
CellTiter 96H AQueous Non-Radioactive Cell Proliferation Assay
(MTS) kit (Promega).
Hematoxylin and eosin staining
Spleens were fixed in 10% buffered formalin, embedded in
paraffin, sectioned at 5 mM and stained with hematoxylin and
eosin.
Gene expression analysis
RNA was isolated from splenic B cells using RNeasy Micro Kit
(QIAGEN) and converted to cDNA using a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems Inc). Real-time
polymerase chain reaction (PCR) was performed with a Taqman
system on a 7900HT Real-Time machine (Applied Biosystems
Inc). The primer sequences for amplification of BAFFR cDNA
were CCTCCGCTCAAAGAAGATGCA (forward primer) and
GTGGAGCCCAGTTCTGT (reverse primer). Data were ana-
lyzed using SDS 2.3 software (Applied Biosystems Inc) and
normalized to glyceraldehyde-3-phosphate dehydrogenase.
Statistical Analysis
Data are expressed as the mean 6 standard deviation (SD).
Data were analyzed by a Student’s unpaired t-test with a two-
tailed distribution. Significance was accepted at p,0.05.
Acknowledgments
We thank Jose A. Cancelas for interpreting the histopathology data and
Leesa Sampson for proofreading the manuscript.
Author Contributions
Conceived and designed the experiments: FG SZ. Performed the
experiments: SZ FG. Analyzed the data: FG SZ. Contributed reagents/
materials/analysis tools: XZ RL. Wrote the paper: FG.
References
1. LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function.
Blood 112: 1570–1580.
2. Srivastava B, Lindsley RC, Nikbakht N, Allman D (2005) Models for peripheral
B cell development and homeostasis. Semin Immunol 17: 175–182.
3. Pillai S, Cariappa A, Moran ST (2005) Marginal Zone B cells. Annu Re.
Immunol 23: 161–196.
4. Ollila J, Vihinen M (2005) B cells. Int J Biochem Cell Biol 37: 518–523.
5. Aelst VL, D’Souza-Schorey C (1997) Rho GTPases and signaling networks.
Genes Dev 11: 2295–2322.
6. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420:
629–635.
7. Nobes CD, Hall A (1995) Rho, rac, and cdc42 GTPases regulate the assembly of
multimolecular focal Complexes associated with actin stress fibers, lamellipodia,
and filopodia. Cell 81: 53–62.
RhoA in B Cell Development
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e337738. Lin R, Cerione RA, Manor D (1999) Specific contributions of the small
GTPases Rho, Rac, and Cdc42 to Dbl transformation. J Biol Chem 274:
23633–23641.
9. Guo F, Zheng Y (2004) Involvement of Rho family GTPases in p19Arf or p53
mediated proliferation of primary mouse embryonic fibroblasts. Mol Cell Biol
24: 1426–1438.
10. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ (1998) Rho
family proteins and Ras transformation: the RHOad less traveled gets congested.
Oncogene 17: 1415–1438.
11. Olson MF, Shworth A, Hall A (1995) An essential role for Rho, Rac, and Cdc42
GTPases in cell cycle progression through G1. Science 269: 1270–1272.
12. Saci A, Carpenter CL (2005) RhoA GTPase regulates B cell receptor signaling.
Mol Cell 17: 205–214.
13. Caloca MJ, Zugaza JL, Bustelo XR (2008) Mechanistic analysis of the
amplification and diversifycation events induced by Vav proteins in B-
lymphocytes. J Biol Chem 283: 36454–36464.
14. Cuesta-Mateos C, Lo ´pez-Giral S, Alfonso-Pe ´rez M, de Soria VG, Loscertales J,
et al. (2010) Analysis of migratory and prosurvival pathways induced by the
homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic
leukemia. Exp Hematol 38: 756–764.
15. Walmsley MJ, Ooi SK, Reynolds LF, Smith SH, Ruf S, et al. (2003) Critical
roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science
302: 459–462.
16. Guo F, Velu CS, Grimes HL, Zheng Y (2009) Rho GTPase Cdc42 is essential
for B lymphocyte development and activation. Blood 114: 2909–2916.
17. Zheng Y (2001) Dbl family guanine nucleotide exchange factors. Trends
Biochem Sci 26: 724–732.
18. Bishop AL, Hall A (2000) Rho GTPases and their effector proteins. Biochem J
348: 241–255.
19. Guo F, Debidda M, Yang L, Williams DA, Zheng Y (2006) Genetitic deletion of
Rac1 GTPase reveals its critical role in actin stress fiber formation and focal
adhesion complex assembly. J Biol Chem 281: 18652–18659.
20. Debreceni B, Gao Y, Guo F, Zhu K, Jia B, et al. (2004) Mechanisms of guanine
nucleotide exchange and Rac-mediated signaling revealed by a dominant
negative trio mutant. J Biol Chem 279: 2777–2786.
21. Jackson B, Peyrollier K, Pedersen E, Basse A, Karlsson R, et al. (2011) RhoA is
dispensable for skin development, but crucial for contraction and directly
migration of keratinocytes. Mol Biol Cell 22: 593–605.
22. Katayama K, Melendez J, Baumann JM, Leslie JR, Chauhan BK, et al. (2011)
Loss of RhoA in neural progenitor cells causes disruption of adherens and
hyperproliferation. Proc Natl Acad Sci U S A 108: 7607–7612.
23. Melendez J, Stengel K, Zhou X, Chauhan BK, Debidda M, et al. (2011) RhoA
GTPase is dispensable for actomyosin regulation but is essential for mitosis in
primary mouse embryonic fibroblasts. J Biol Chem 286: 15132–15137.
24. Rickert RC, Rajewsky K, Roes J (1995) Impairment of T-cell-dependent B-cell
responses and B-1 cell development in CD19-deficient mice. Nature 376:
352–355.
25. Croker BA, Tarlinton DM, Cluse LA, Tuxen AJ, Light A, et al. (2002) The Rac2
guanosine triphosphatase regulates B lymphocyte antigen receptor responses and
chemotaxis and is required for establishment of B-1a and marginal zone B
lymphocytes. J Immunol 168: 3376–3386.
26. Henderson RB, Grys K, Vehlow A, de Bettignies C, Zachacz A, et al. (2010) A
novel Rac-dependent checkpoint in B cell development controls entry into the
splenic white pulp and cell survival. J Exp Med 207: 837–853.
27. Kim CH, Broxmeyer HE (1999) Chemokines: signal lamps for trafficking of T
and B cells for development and effector function. J Leukoc Biol 65: 6–15.
28. Rickert RC, Roes J, Rajewsky K (1997) B lymphocyte-specific, Cre-mediated
mutagenesis in mice. Nucleic Acids Res 25: 1317–1318.
29. Khan WN (2009) B cell receptor and BAFF receptor signaling regulation of B
cell homeostasis. J Immunol 183: 3561–3567.
30. Anwar KN, Fazal F, Malik AB, Rahman A (2004) RhoA/Rho-associated kinase
pathway selectively regulates thrombin-induced intercellular adhesion molecule-
1 expression in endothelial cells via activation of I kappa B kinase beta and
phosphorylation of RelA/p65. J Immunol 173: 6965–6972.
31. Haudenschild DR, Chen J, Steklov N, Lotz MK, D’Lima DD (2009)
Characterization of the chondrocyte actin cytoskeleton in living three-
dimensional culture: response to anabolic and catabolic stimuli. Mol Cell
Biomech 6: 135–144.
32. Perona R, Montaner S, Saniger L, Sa ´nchez-Pe ´rez I, Bravo R, et al. (1997)
Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins.
Genes Dev 11: 463–475.
33. So T, Lee SW, Croft M (2006) Tumor necrosis factor/tumor necrosis factor
receptor family members that positively regulate immunity. Int J Hematol 83:
1–11.
34. Salzer U, Jennings S, Grimbacher B (2007) To switch or not to switch–the
opposing roles of TACI in terminal B cell differentiation. Eur J Immunol 37:
17–20.
35. Shulga-Morskaya S, Dobles M, Walsh ME, Ng LG, MacKay F, et al. (2004) B
cell-activating factor belonging to the TNF family acts through separate
receptors to support B cell survival and T cell-independent antibody formation.
J Immunol 173: 2331–2341.
36. Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: structure,
function and signaling. Semin Immunol 18: 263–275.
37. Badr G, Borhis G, Lefevre EA, Chaoul N, Deshayes F, et al. (2008) BAFF
enhances chemotaxis of primary human B cells: a particular synergy between
BAFF and CXCL13 on memory B cells. Blood 111: 2744–2754.
38. Rohlmann A, Gotthardt M, Hammer RE, Herz J (1998) Inducible inactivation
of hepatic LRP gene by cre-mediated recombination confirms role of LRP in
clearance of chylomicron remnants. J Clin Invest 101: 689–695.
RhoA in B Cell Development
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33773